About us

 
 

Harvest One

Harvest One Capital Inc. (TSXV:HVST) is an early-entry global cannabis company servicing both the medical and recreational cannabis markets, in Canada and internationally. Shareholders have significant exposure to the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. 

Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation licence, making Harvest One one of only a few companies globally with the capacity to commercially cultivate medicinal grade cannabis in a federally regulated environment.

 

Our Brands


 
 
 

United Greeneries

United Greeneries is a Canadian ACMPR Licensed Producer and is Harvest One’s horticultural arm. United Greeneries has two main facilities, the Duncan Facility and the Lucky Lake Facility. United Greeneries' Duncan Facility is licensed to cultivate medical marihuana by Health Canada pursuant to its ACMPR License. Management of United Greeneries anticipates that the Duncan Facility will be issued a full ACMPR distribution license in the second quarter of 2017. The Lucky Lake Facility is at the ACMPR security clearance stage of review.

On June 28, 2016, Health Canada approved United Greeneries LP as an authorized Licensed Producer at the Duncan Facility. The Duncan Facility has approximately 10,000 ft² of cultivation area and high compliance items such as a Level 8 Narcotics Vault and a full service in-house biochemical and analytical laboratory. The Duncan Facility has cultivation capacity of approximately 1,000 kg of cannabis per annum.

The Lucky Lake Facility, located in Lucky Lake, Saskatchewan is a 62,000 ft2 concrete agricultural facility sitting on over 18 acres of land which is wholly-owned by United Greeneries.

 

  • ACMPR Licensed Producer
     

  • Site 1 with a production capacity of ~1,000 kg/year and planned greenhouse expansion plan– in 3 phases – to increase production capacity up to ~50,000 kg/year.  
     

  • Site 2 with a production capacity of 12,000 kg/year, with LP application underway

 


 
 

Satipharm

Satipharm is specialised in the development and manufacturing of cannabis-based health products and is Harvest One’s medical and health brand.

Satipharm’s goal is to develop cutting-edge technology and pharmaceutical-grade cannabis products for the medical and health-based cannabis markets.

Satipharm believes commercialization of its signature Gelpell® technology for cannabinoid products will transform the company into a global leader in the medical and health-based cannabis industry. Production of 10mg and 50mg Gelpell® microgel capsules began in May 2015. In 2017, Satipharm’s marketing campaign is focused on near-term growth and driving sales first in Germany and Poland with entry into additional European Union countries to follow. The company is concurrently preparing to import its products into Canada and Australia.

Satipharm is dedicated to growing its portfolio of delivery technology IP with further expansion plans targeting introduction of other formulations including THC.

 

  • Flagship Gelpell® Microgel Capsules to lead growth
     

  • Near-term growth from supplement sales in EU
     

  • Mid-term growth from entry into regulated markets (Canada, Australia, etc.)
     

  • Significant growth opportunities with future product development

 
 
 

WANT TO KNOW MORE?

Investors

Press

 
background_03.jpg